Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer

Cancer Letters

Volumn 259, Issue 1, 2008, Pages 39-49

  Lee, Sang Hyub ^a,b   Ryu, Ji Kon ^a   Lee, Kyeung Yeup ^a   Woo, Sang Myung ^a   Park, Joo Kyung ^a   Yoo, Ji Won ^a   Kim, Yong Tae ^a   Yoon, Yong Bum ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Akt; Apigenin; Gemcitabine; NF B; Pancreatic cancer

Indexed keywords

APIGENIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APIGENIN; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; MICE; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36849075271     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.09.015     Document Type: Article

References (38)

1. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
2. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 (1997) 2403-2413
3. Abbruzzese J.L. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95 (2002) 941-945
4. Carmichael J., Fink U., Russell R.C., Spittle M.F., Harris A.L., Spiessi G., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73 (1996) 101-105
5. Bharti A.C., and Aggarwal B.B. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann. N. Y. Acad. Sci. 973 (2002) 392-395
6. Li Y., Ellis K.L., Ali S., El-Rayes B.F., Nedeljkovic-Kurepa A., Kucuk O., et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28 (2004) e90-e95
7. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 65 (2005) 9064-9072
8. Kuo M.L., Lee K.C., and Lin J.K. Genotoxicities of nitropyrenes and their modulation by apigenin, tannic acid, ellagic acid and indole-3-carbinol in the Salmonella and CHO systems. Mutat. Res. 270 (1992) 87-95
9. Chaumontet C., Bex V., Gaillard-Sanchez I., Seillan-Heberden C., Suschetet M., and Martel P. Apigenin and tangeretin enhance gap junctional intercellular communication in rat liver epithelial cells. Carcinogenesis 15 (1994) 2325-2330
10. Kuo M.L., and Yang N.C. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Commun. 212 (1995) 767-775
11. Gupta S., Afaq F., and Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 287 (2001) 914-920
12. Duthie G., and Crozier A. Plant-derived phenolic antioxidants. Curr. Opin. Clin. Nutr. Metab. Care 3 (2000) 447-451
13. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., and Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol. Carcinog. 28 (2000) 102-110
14. Yin F., Giuliano A.E., Law R.E., and Van Herle A.J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 21 (2001) 413-420
15. Yin F., Giuliano A.E., and Van Herle A.J. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res. 19 (1999) 4297-4303
16. Ruiz P.A., and Haller D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J. Nutr. 136 (2006) 664-671
17. Shukla S., and Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res. 10 (2004) 3169-3178
18. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60 (2000) 2926-2935
19. Berlin J.D., and Rothenberg M.L. Chemotherapeutic advances in pancreatic cancer. Curr. Oncol. Rep. 5 (2003) 219-226
20. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9 (2004) 282-294
21. Arends J.J., Sleeboom H.P., Leys M.B., Ten Bokkel Huinink D., de Jong R.S., Smit J.M., et al. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br. J. Cancer 92 (2005) 445-448
22. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2 (2002) 277-288
23. Zornig M., Hueber A., Baum W., and Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta 1551 (2001) F1-F37
24. Ding H.F., and Fisher D.E. Induction of apoptosis in cancer: new therapeutic opportunities. Ann. Med. 34 (2002) 451-469
25. Clarke R.B. p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res. 5 (2003) 162-163
26. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
27. Bondar V.M., Sweeney-Gotsch B., Andreeff M., Mills G.B., and McConkey D.J. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1 (2002) 989-997
28. Li Y., and Sarkar F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8 (2002) 2369-2377
29. Rahman K.M., Li Y., and Sarkar F.H. Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr. Cancer 48 (2004) 84-94
30. Hill M.M., and Hemmings B.A. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol. Ther. 93 (2002) 243-251
31. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19 (2005) 342-353
32. Way T.D., Kao M.C., and Lin J.K. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 279 (2004) 4479-4489
33. Schniewind B., Christgen M., Kurdow R., Haye S., Kremer B., Kalthoff H., et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int. J. Cancer 109 (2004) 182-188
34. Liu J.R., Fletcher B., Page C., Hu C., Nunez G., and Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70 (1998) 398-403
35. Decaudin D., Geley S., Hirsch T., Castedo M., Marchetti P., Macho A., et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 57 (1997) 62-67
36. Stoetzer O.J., Nussler V., Darsow M., Gullis E., Pelka-Fleischer R., Scheel U., et al. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 10 Suppl. 3 (1996) S18-S22
37. Bold R.J., Chandra J., and McConkey D.J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. 6 (1999) 279-285
38. Xu Z.W., Friess H., Buchler M.W., and Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol. 49 (2002) 504-510